Aclaris Therapeutics’ (ACRS) Neutral Rating Reiterated at HC Wainwright

HC Wainwright reiterated their neutral rating on shares of Aclaris Therapeutics (NASDAQ:ACRS) in a report published on Monday morning, Benzinga reports. HC Wainwright also issued estimates for Aclaris Therapeutics’ FY2024 earnings at ($0.66) EPS.

Separately, StockNews.com raised Aclaris Therapeutics from a sell rating to a hold rating in a research report on Thursday, July 25th. Seven equities research analysts have rated the stock with a hold rating and one has given a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of Hold and an average price target of $22.25.

Aclaris Therapeutics Stock Up 1.6 %

Shares of NASDAQ ACRS opened at $1.27 on Monday. The business’s 50 day moving average price is $1.24 and its 200 day moving average price is $1.21. The firm has a market cap of $90.51 million, a P/E ratio of -1.17 and a beta of 0.27. Aclaris Therapeutics has a 52 week low of $0.59 and a 52 week high of $8.28.

Aclaris Therapeutics (NASDAQ:ACRS) last announced its quarterly earnings data on Wednesday, August 7th. The biotechnology company reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.19) by $0.04. The business had revenue of $2.77 million during the quarter, compared to analysts’ expectations of $1.74 million. Aclaris Therapeutics had a negative net margin of 248.28% and a negative return on equity of 61.03%. As a group, research analysts expect that Aclaris Therapeutics will post -0.77 earnings per share for the current year.

Insider Buying and Selling

In other news, major shareholder Braden Michael Leonard acquired 528,621 shares of the business’s stock in a transaction on Thursday, June 13th. The stock was bought at an average price of $1.15 per share, with a total value of $607,914.15. Following the completion of the acquisition, the insider now owns 11,007,134 shares of the company’s stock, valued at $12,658,204.10. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Over the last three months, insiders have bought 2,609,123 shares of company stock valued at $2,976,646. Corporate insiders own 6.40% of the company’s stock.

Hedge Funds Weigh In On Aclaris Therapeutics

A number of hedge funds have recently bought and sold shares of the business. Vontobel Holding Ltd. raised its stake in shares of Aclaris Therapeutics by 128.8% during the 4th quarter. Vontobel Holding Ltd. now owns 30,268 shares of the biotechnology company’s stock worth $32,000 after buying an additional 17,040 shares during the period. Strs Ohio lifted its holdings in Aclaris Therapeutics by 256.7% during the fourth quarter. Strs Ohio now owns 193,000 shares of the biotechnology company’s stock valued at $202,000 after purchasing an additional 138,900 shares in the last quarter. BML Capital Management LLC acquired a new stake in shares of Aclaris Therapeutics in the fourth quarter valued at about $686,000. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of Aclaris Therapeutics by 115.5% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 43,784 shares of the biotechnology company’s stock worth $46,000 after purchasing an additional 23,467 shares in the last quarter. Finally, Monaco Asset Management SAM acquired a new position in shares of Aclaris Therapeutics during the 4th quarter worth about $1,028,000. Hedge funds and other institutional investors own 98.34% of the company’s stock.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.